471 related articles for article (PubMed ID: 29339271)
1. Early Increase in Complement Terminal Pathway Activation Marker sC5b-9 Is Predictive for the Development of Thrombotic Microangiopathy after Stem Cell Transplantation.
Horváth O; Kállay K; Csuka D; Mező B; Sinkovits G; Kassa C; Stréhn A; Csordás K; Sinkó J; Prohászka Z; Kriván G
Biol Blood Marrow Transplant; 2018 May; 24(5):989-996. PubMed ID: 29339271
[TBL] [Abstract][Full Text] [Related]
2. Validation of Early Increase in Complement Activation Marker sC5b-9 as a Predictive Biomarker for the Development of Thrombotic Microangiopathy After Stem Cell Transplantation.
Mezö B; Horváth O; Sinkovits G; Veszeli N; Kriván G; Prohászka Z
Front Med (Lausanne); 2020; 7():569291. PubMed ID: 33117830
[TBL] [Abstract][Full Text] [Related]
3. Plasma levels of complement activation fragments C3b and sC5b-9 significantly increased in patients with thrombotic microangiopathy after allogeneic stem cell transplantation.
Qi J; Wang J; Chen J; Su J; Tang Y; Wu X; Ma X; Chen F; Ruan C; Zheng XL; Wu D; Han Y
Ann Hematol; 2017 Nov; 96(11):1849-1855. PubMed ID: 28801815
[TBL] [Abstract][Full Text] [Related]
4. Harmonizing Definitions for Diagnostic Criteria and Prognostic Assessment of Transplantation-Associated Thrombotic Microangiopathy: A Report on Behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research.
Schoettler ML; Carreras E; Cho B; Dandoy CE; Ho VT; Jodele S; Moissev I; Sanchez-Ortega I; Srivastava A; Atsuta Y; Carpenter P; Koreth J; Kroger N; Ljungman P; Page K; Popat U; Shaw BE; Sureda A; Soiffer R; Vasu S
Transplant Cell Ther; 2023 Mar; 29(3):151-163. PubMed ID: 36442770
[TBL] [Abstract][Full Text] [Related]
5. The alternative complement pathway activation product Ba as a marker for transplant-associated thrombotic microangiopathy.
Sartain S; Shubert S; Wu MF; Wang T; Martinez C
Pediatr Blood Cancer; 2020 Mar; 67(3):e28070. PubMed ID: 31774252
[TBL] [Abstract][Full Text] [Related]
6. Transplantation-Associated Thrombotic Microangiopathy Risk Stratification: Is There a Window of Opportunity to Improve Outcomes?
Jodele S; Dandoy CE; Sabulski A; Koo J; Lane A; Myers KC; Wallace G; Chima RS; Teusink-Cross A; Hirsch R; Ryan TD; Benoit S; Davies SM
Transplant Cell Ther; 2022 Jul; 28(7):392.e1-392.e9. PubMed ID: 35490975
[TBL] [Abstract][Full Text] [Related]
7. Thrombotic Microangiopathy Following Pediatric Autologous Hematopoietic Cell Transplantation: A Report of Significant End-Organ Dysfunction in Eculizumab-Treated Survivors.
Schoettler M; Lehmann L; Li A; Ma C; Duncan C
Biol Blood Marrow Transplant; 2019 May; 25(5):e163-e168. PubMed ID: 30639820
[TBL] [Abstract][Full Text] [Related]
8. Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation.
Jodele S; Fukuda T; Mizuno K; Vinks AA; Laskin BL; Goebel J; Dixon BP; Chima RS; Hirsch R; Teusink A; Lazear D; Lane A; Myers KC; Dandoy CE; Davies SM
Biol Blood Marrow Transplant; 2016 Feb; 22(2):307-315. PubMed ID: 26456258
[TBL] [Abstract][Full Text] [Related]
9. Early Elevation of Complement Factor Ba Is a Predictive Biomarker for Transplant-Associated Thrombotic Microangiopathy.
Okamura H; Nakamae H; Shindo T; Ohtani K; Hidaka Y; Ohtsuka Y; Makuuchi Y; Kuno M; Takakuwa T; Harada N; Nishimoto M; Nakashima Y; Koh H; Hirose A; Nakamae M; Wakamiya N; Hino M; Inoue N
Front Immunol; 2021; 12():695037. PubMed ID: 34326846
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics of pediatric allogeneic hematopoietic stem cell transplantation-associated thrombotic microangiopathy (TA-TMA): a retrospective single-center analysis.
Luo L; Xiong H; Chen Z; Yang L; Sun M; Lu W; Tao F; Wang Z; Li J; Li Z; Tang S
Clin Transl Oncol; 2023 Aug; 25(8):2451-2461. PubMed ID: 36973479
[TBL] [Abstract][Full Text] [Related]
11. Use of Eculizumab in Pediatric Patients with High-Risk Transplantation-Associated Thrombotic Microangiopathy: Outcomes and Risk Factors Associated with Response and Survival. A Retrospective Study on Behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC).
Benítez Carabante MI; Bueno D; Alonso García L; López Torija I; Marsal J; Fernandez Navarro JM; Uria Oficialdegui ML; Panesso M; Molina B; Beléndez Bieler C; Palomo P; Pérez Martínez A; Diaz-de-Heredia C
Transplant Cell Ther; 2024 Jun; 30(6):601.e1-601.e13. PubMed ID: 38521410
[TBL] [Abstract][Full Text] [Related]
12. Increased Body Mass Index Augments Endothelial Injury and Clinical Outcomes after Hematopoietic Stem Cell Transplantation.
Koo J; Ziady AG; Reynaud D; Abdullah S; Luebbering N; Kahn S; Langenberg L; Strecker L; Lake K; Dandoy CE; Lane A; Myers KC; Sabulski A; Good S; Nalapareddy K; Solomon M; Siefert ME; Skala E; Jodele S; Davies SM
Transplant Cell Ther; 2023 Nov; 29(11):704.e1-704.e8. PubMed ID: 37625594
[TBL] [Abstract][Full Text] [Related]
13. Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab.
Jodele S; Dandoy CE; Lane A; Laskin BL; Teusink-Cross A; Myers KC; Wallace G; Nelson A; Bleesing J; Chima RS; Hirsch R; Ryan TD; Benoit S; Mizuno K; Warren M; Davies SM
Blood; 2020 Mar; 135(13):1049-1057. PubMed ID: 31932840
[TBL] [Abstract][Full Text] [Related]
14. Late transplant-associated thrombotic microangiopathy verified in bone marrow biopsy specimens is associated with chronic GVHD and viral infections.
Hill W; Sotlar K; Hautmann A; Kolb HJ; Ullmann J; Hausmann A; Schmidt M; Tischer J; Pham TT; Rank A; Hoechstetter MA
Eur J Haematol; 2024 May; 112(5):819-831. PubMed ID: 38243840
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults.
Jodele S; Davies SM; Lane A; Khoury J; Dandoy C; Goebel J; Myers K; Grimley M; Bleesing J; El-Bietar J; Wallace G; Chima RS; Paff Z; Laskin BL
Blood; 2014 Jul; 124(4):645-53. PubMed ID: 24876561
[TBL] [Abstract][Full Text] [Related]
16. New approaches in the diagnosis, pathophysiology, and treatment of pediatric hematopoietic stem cell transplantation-associated thrombotic microangiopathy.
Jodele S; Dandoy CE; Myers KC; El-Bietar J; Nelson A; Wallace G; Laskin BL
Transfus Apher Sci; 2016 Apr; 54(2):181-90. PubMed ID: 27156964
[TBL] [Abstract][Full Text] [Related]
17. High mortality in hematopoietic stem cell transplant-associated thrombotic microangiopathy with and without concomitant acute graft-versus-host disease.
Kraft S; Bollinger N; Bodenmann B; Heim D; Bucher C; Lengerke C; Kleber M; Tsakiris DA; Passweg J; Tzankov A; Medinger M
Bone Marrow Transplant; 2019 Apr; 54(4):540-548. PubMed ID: 30108323
[TBL] [Abstract][Full Text] [Related]
18. [Allogeneic hematopoietic stem cell transplantation associated thrombotic microangiopathy: 16 cases report and literature review].
Han W; Han Y; Chen J; Ma X; Chen F; Wu XJ; Qi JQ; Qiu HY; Sun AN; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2016 Aug; 37(8):666-70. PubMed ID: 27587247
[TBL] [Abstract][Full Text] [Related]
19. New insights into risk factors for transplant-associated thrombotic microangiopathy in pediatric HSCT.
Elfeky R; Lucchini G; Lum SH; Ottaviano G; Builes N; Nademi Z; Battersby A; Flood T; Owens S; Cant AJ; Young H; Greener S; Walsh P; Kavanagh D; Annavarapu S; Rao K; Amrolia P; Chiesa R; Worth A; Booth C; Skinner R; Doncheva B; Standing J; Gennery AR; Qasim W; Slatter M; Veys P
Blood Adv; 2020 Jun; 4(11):2418-2429. PubMed ID: 32492158
[TBL] [Abstract][Full Text] [Related]
20. Systematic Review of Signs and Symptoms Associated with Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy.
Dandoy CE; Tsong WH; Sarikonda K; McGarvey N; Perales MA
Transplant Cell Ther; 2023 Apr; 29(4):282.e1-282.e9. PubMed ID: 36592719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
